Interim Results of Independent Evaluation Confirm That Microbix' Flu Vaccine Technology Works
16-Mar-2006
Microbix Biosystems Inc. announced that interim findings of an independent evaluation have confirmed that its proprietary technology delivers a significant increase in the yield of influenza virus used in the manufacture of flu vaccine. The independent laboratory found that Microbix' technology results in more than a two-fold increase in the amount of human influenza virus produced through conventional industry methods. More experiments are scheduled, and the Company expects to announce final results in the near future.
Once this phase is completed, the study will focus on the application of the technology to avian flu virus, which should be completed this summer.
Other news from the department science
